<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Ketamine - Complete Profile</title>
    <link rel="stylesheet" href="/Dyo-s-Dubious-Domain/style.css">
</head>

<body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/Dyo-s-Dubious-Domain/" class="site-title">Dyo's Dubious Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/Dyo-s-Dubious-Domain/">Home</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/about/">About</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚Üí <a href="/dyos-domain/dissociatives/">Dissociatives</a> ‚Üí <span>Ketamine</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>üåÄ Ketamine</h1>
        <h2 class="chemical-name">2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone</h2>
          <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="Ketamine" 
                data-category="Dissociatives" 
                data-chemical="2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Common Names</h4>
              <span>K</span> ‚Ä¢ <span>Ket</span> ‚Ä¢ <span>Kitty</span> ‚Ä¢ <span>Special K</span> ‚Ä¢ <span>Vitamin K</span>
            </div>
            <div class="name-category">
              <h4>Medical Names</h4>
              <span>Ketalar</span> ‚Ä¢ <span>Ketaset</span> ‚Ä¢ <span>Spravato</span> ‚Ä¢ <span>Esketamine</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>K-hole</span> ‚Ä¢ <span>Wonk</span> ‚Ä¢ <span>Donkey Dust</span> ‚Ä¢ <span>Green</span> ‚Ä¢ <span>Liquid K</span>
            </div>
            <div class="name-category">
              <h4>Clinical Names</h4>
              <span>Ketamine HCl</span> ‚Ä¢ <span>S-Ketamine</span> ‚Ä¢ <span>R-Ketamine</span> ‚Ä¢ <span>Arylcyclohexylamine</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category dissociative">Dissociative</span>
          <span class="legal-status schedule-3">Schedule III</span>
          <span class="duration medium">1-6 hours</span>
          <span class="medical">Medical Use</span>
          <span class="prescription">Prescription</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/assets/substances/ketamine.jpg" alt="Ketamine medical vials and powder" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>üß¨ C‚ÇÅ‚ÇÉH‚ÇÅ‚ÇÜClNO</p>
            <p>MW: 237.73 g/mol</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Pure Ketamine (HCl salt)</h4>
          <ul>
            <li><strong>Appearance:</strong> White crystalline powder or clear liquid</li>
            <li><strong>Texture:</strong> Fine crystalline powder when dried from liquid</li>
            <li><strong>Odor:</strong> Slightly medicinal, chemical smell</li>
            <li><strong>Taste:</strong> Bitter, numbing, distinctly unpleasant</li>
            <li><strong>Solubility:</strong> Highly soluble in water and alcohol</li>
          </ul>
        </div>
        
        <div class="street-forms">
          <h4>Street & Medical Forms</h4>
          <ul>
            <li><strong>Medical Vials:</strong> Clear liquid (50mg/ml, 100mg/ml) in sealed ampoules</li>
            <li><strong>Dried Powder:</strong> White crystalline powder from evaporated liquid</li>
            <li><strong>Spravato Nasal Spray:</strong> FDA-approved esketamine for depression</li>
            <li><strong>Pills/Capsules:</strong> Less common, often mixed with other substances</li>
            <li><strong>Shards:</strong> Large crystal formations from slow evaporation</li>
          </ul>
        </div>
        
        <div class="adulterants-warning">
          <h4>‚ö†Ô∏è Purity & Adulterants</h4>
          <p><strong>Pharmaceutical:</strong> Medical-grade ketamine is extremely pure</p>
          <p><strong>Veterinary sources:</strong> High purity but may contain preservatives</p>
          <p><strong>Street powder:</strong> May be cut with caffeine, creatine, or other dissociatives</p>
          <p><strong>Analogs:</strong> 2-FDCK, DCK, and other arylcyclohexylamines sold as ketamine</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines</h3>
      <div class="dosage-chart">
        <div class="dose-range threshold">
          <span class="range-label">Threshold</span>
          <span class="dose-amount">10-20mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range light">
          <span class="range-label">Light</span>
          <span class="dose-amount">20-50mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range common">
          <span class="range-label">Common</span>
          <span class="dose-amount">50-125mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Strong</span>
          <span class="dose-amount">125-200mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">K-hole</span>
          <span class="dose-amount">200mg+</span>
          <div class="dose-bar"></div>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>Route-Dependent Dosing</h4>
        <ul>
          <li><strong>Intramuscular (IM):</strong> 75-125mg for anesthetic doses</li>
          <li><strong>Insufflated (nasal):</strong> Most common recreational route, doses above</li>
          <li><strong>Oral:</strong> 200-500mg (low bioavailability, longer duration)</li>
          <li><strong>Sublingual:</strong> 50-200mg (higher bioavailability than oral)</li>
          <li><strong>Intravenous (IV):</strong> Medical only - 0.5-2mg/kg for anesthesia</li>
          <li><strong>Therapeutic doses:</strong> 0.5mg/kg IV for depression treatment</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>Critical Warning:</strong> K-hole doses can cause complete dissociation from body and environment. Use only in safe settings with sober supervision.</p>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline (Insufflated)</h4>
        <div class="timeline-item">
          <span class="time">T+0:05-0:15</span>
          <span class="effect">Onset - numbness, mild dissociation</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+0:15-1:00</span>
          <span class="effect">Peak - dissociation, analgesia, altered perception</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+1:00-2:00</span>
          <span class="effect">Plateau - sustained dissociative effects</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+2:00-4:00</span>
          <span class="effect">Comedown - gradual return to baseline</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+4:00-24:00</span>
          <span class="effect">After effects - possible mood lift, fatigue</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category positive">
          <h4>‚úÖ Therapeutic Effects</h4>
          <ul>
            <li>Rapid antidepressant effects</li>
            <li>Complete pain relief (analgesia)</li>
            <li>Ego dissolution and perspective shift</li>
            <li>Reduced rumination and negative thought patterns</li>
            <li>Mystical/spiritual experiences</li>
            <li>Enhanced neuroplasticity</li>
            <li>Anxiety reduction (at lower doses)</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>‚ùå Challenging Effects</h4>
          <ul>
            <li>Complete detachment from reality (K-hole)</li>
            <li>Nausea and vomiting</li>
            <li>Loss of motor coordination</li>
            <li>Confusion and memory impairment</li>
            <li>Increased heart rate and blood pressure</li>
            <li>Bladder irritation (chronic use)</li>
            <li>Potential for psychological dependence</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>Ketamine is a non-competitive NMDA (N-methyl-D-aspartate) receptor antagonist that blocks glutamate neurotransmission. This disrupts normal brain network communication, leading to dissociative effects and rapid antidepressant action through increased BDNF (brain-derived neurotrophic factor) and enhanced synaptic plasticity.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>NMDA receptors</strong></span>
            <span class="affinity">Non-competitive antagonist (IC50: 0.53 ŒºM)</span>
            <span class="function">Primary dissociative and antidepressant effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Dopamine D2 receptors</strong></span>
            <span class="affinity">Moderate affinity antagonist</span>
            <span class="function">May contribute to psychotomimetic effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Serotonin transporter</strong></span>
            <span class="affinity">Weak inhibition</span>
            <span class="function">Minor contribution to antidepressant effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Norepinephrine transporter</strong></span>
            <span class="affinity">Weak inhibition</span>
            <span class="function">Cardiovascular stimulation</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>HCN1 channels</strong></span>
            <span class="affinity">Antagonist activity</span>
            <span class="function">Contributes to antidepressant mechanism</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Opioid receptors</strong></span>
            <span class="affinity">Weak Œº-opioid agonist</span>
            <span class="function">Minor analgesic contribution</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Primary Pathway:</strong> N-demethylation by CYP3A4/2B6 ‚Üí Norketamine (active metabolite)</p>
          <p><strong>Secondary metabolites:</strong> Hydroxynorketamines (HNKs) - may mediate antidepressant effects</p>
          <p><strong>Ketamine half-life:</strong> 2.5-3 hours (IV), 4-5 hours (oral)</p>
          <p><strong>Norketamine half-life:</strong> 7-11 hours (extends overall effects)</p>
          <p><strong>Bioavailability:</strong> 100% (IV), 93% (IM), 45% (intranasal), 20% (oral)</p>
          <p><strong>Peak plasma:</strong> Immediate (IV), 30 min (IM), 20-30 min (intranasal)</p>
        </div>

        <h4>Antidepressant Mechanisms</h4>
        <div class="neurotoxicity-info">
          <p><strong>BDNF upregulation:</strong> Increased brain-derived neurotrophic factor promotes neuroplasticity</p>
          <p><strong>mTOR activation:</strong> Stimulates protein synthesis and synaptic growth</p>
          <p><strong>AMPA potentiation:</strong> Enhanced glutamate signaling through AMPA receptors</p>
          <p><strong>Default mode network:</strong> Disrupts overactive rumination circuits</p>
          <p><strong>Spine formation:</strong> Promotes new dendritic spine growth within hours</p>
        </div>

        <h4>Unique Pharmacological Properties</h4>
        <ul>
          <li><strong>Stereoisomers:</strong> S-ketamine (esketamine) is 3-4x more potent than R-ketamine</li>
          <li><strong>Rapid onset:</strong> Antidepressant effects within hours, not weeks</li>
          <li><strong>Dissociative dose-response:</strong> Higher doses produce complete ego dissolution</li>
          <li><strong>Anesthetic properties:</strong> Complete pain relief without respiratory depression</li>
          <li><strong>Neuroplasticity:</strong> Enhances brain's ability to form new connections</li>
          <li><strong>Tolerance:</strong> Develops rapidly with frequent use, requiring dose escalation</li>
        </ul>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†Ô∏è Safety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® Critical Warnings</h4>
          <ul>
            <li><strong>Bladder toxicity:</strong> Chronic use causes severe urinary tract damage</li>
            <li><strong>Respiratory depression:</strong> Risk increases with high doses or mixing</li>
            <li><strong>Complete dissociation:</strong> K-hole renders users completely helpless</li>
            <li><strong>Cardiovascular stress:</strong> Increases heart rate and blood pressure</li>
            <li><strong>Psychological dependence:</strong> Highly habit-forming for some users</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>üõ°Ô∏è Harm Reduction</h4>
          <ul>
            <li>Never use alone - always have a sober sitter present</li>
            <li>Use in safe environment - remove hazards, soft surfaces</li>
            <li>Avoid mixing with alcohol or other depressants</li>
            <li>Take frequent breaks to prevent bladder damage</li>
            <li>Stay hydrated but don't overconsume water</li>
            <li>Test substances - many analogs sold as ketamine</li>
          </ul>
        </div>
      </div>

      <div class="contraindications">
        <h4>üö´ Contraindications</h4>
        <p><strong>Do not use if you have:</strong> Uncontrolled high blood pressure, heart conditions, active psychosis, bladder problems, or history of ketamine dependence. Avoid during pregnancy and with certain psychiatric medications.</p>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏è Drug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Dangerous</h4>
          <ul>
            <li><strong>CNS Depressants:</strong> Alcohol, benzos, opioids increase respiratory depression risk</li>
            <li><strong>MAOIs:</strong> May prolong and intensify effects unpredictably</li>
            <li><strong>Stimulants:</strong> Dangerous cardiovascular strain, especially cocaine</li>
            <li><strong>High blood pressure meds:</strong> May cause dangerous BP fluctuations</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° Risky</h4>
          <ul>
            <li><strong>Cannabis:</strong> May increase confusion and anxiety</li>
            <li><strong>Psychedelics:</strong> Unpredictable interactions, overwhelming experiences</li>
            <li><strong>DXM:</strong> Both NMDA antagonists - increased dissociation</li>
            <li><strong>Nitrous oxide:</strong> Risk of falls during dissociation</li>
          </ul>
        </div>
        
        <div class="interaction caution">
          <h4>üü† Use Caution</h4>
          <ul>
            <li><strong>Antidepressants:</strong> May reduce ketamine's antidepressant effects</li>
            <li><strong>Anticonvulsants:</strong> May affect metabolism and duration</li>
            <li><strong>CYP enzyme inducers:</strong> Can alter ketamine metabolism</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏è Legal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>üá∫üá∏ United States</h4>
            <p><strong>Schedule III</strong> - Legal for medical use. Spravato (esketamine) FDA-approved for treatment-resistant depression. Possession without prescription is illegal.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá¨üáß United Kingdom</h4>
            <p><strong>Class B</strong> - Up to 5 years for possession, 14 years for supply. Legal for medical and veterinary use.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá®üá¶ Canada</h4>
            <p><strong>Schedule I</strong> - Controlled substance. Legal for medical use, illegal for recreational possession.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá¶üá∫ Australia</h4>
            <p><strong>Schedule 8</strong> - Controlled drug for medical use. Recently approved for treatment-resistant depression.</p>
          </div>
        </div>
        
        <div class="therapeutic-status">
          <h4>üè• Medical Applications</h4>
          <p>Ketamine is widely used as an anesthetic and increasingly prescribed for treatment-resistant depression. FDA-approved Spravato (esketamine) nasal spray available through certified treatment centers. Off-label ketamine therapy expanding rapidly.</p>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Culture</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1962</span>
          <p>Synthesized by Calvin Stevens at Parke-Davis as PCP replacement</p>
        </div>
        <div class="history-event">
          <span class="year">1964</span>
          <p>First human trials show dissociative anesthetic properties</p>
        </div>
        <div class="history-event">
          <span class="year">1970</span>
          <p>FDA approval for human anesthetic use</p>
        </div>
        <div class="history-event">
          <span class="year">1970s</span>
          <p>Extensive use in Vietnam War field medicine</p>
        </div>
        <div class="history-event">
          <span class="year">1999</span>
          <p>Scheduled as controlled substance due to recreational use</p>
        </div>
        <div class="history-event">
          <span class="year">2000s</span>
          <p>Research reveals rapid antidepressant properties</p>
        </div>
        <div class="history-event">
          <span class="year">2019</span>
          <p>FDA approves Spravato for treatment-resistant depression</p>
        </div>
        <div class="history-event">
          <span class="year">2020s</span>
          <p>Ketamine therapy clinics proliferate worldwide</p>
        </div>
      </div>

      <div class="cultural-impact">
        <h4>Medical & Cultural Impact</h4>
        <p>Ketamine represents a unique bridge between medical utility and consciousness exploration. Its discovery of rapid antidepressant effects revolutionized psychiatric treatment, while its dissociative properties have made it popular in both club culture and therapeutic psychedelic communities.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>Treatment-Resistant Depression</h4>
          <p>Extensive clinical trials show 70% response rates in patients who failed multiple antidepressants. Spravato treatment centers now available worldwide with ongoing expansion.</p>
        </div>
        
        <div class="research-item">
          <h4>Suicidal Ideation</h4>
          <p>Rapid reduction in suicidal thoughts within hours of treatment, leading to emergency ketamine protocols in psychiatric settings.</p>
        </div>
        
        <div class="research-item">
          <h4>Chronic Pain Management</h4>
          <p>Low-dose ketamine infusions showing promise for fibromyalgia, neuropathic pain, and complex regional pain syndrome.</p>
        </div>
        
        <div class="research-item">
          <h4>PTSD & Trauma</h4>
          <p>Studies investigating ketamine's ability to disrupt traumatic memory reconsolidation and reduce PTSD symptoms.</p>
        </div>
        
        <div class="research-item">
          <h4>Addiction Treatment</h4>
          <p>Research into ketamine-assisted psychotherapy for alcohol and cocaine dependence, leveraging neuroplasticity effects.</p>
        </div>
        
        <div class="research-item">
          <h4>Bladder Toxicity Prevention</h4>
          <p>Ongoing research into mechanisms of ketamine cystitis and potential protective treatments for chronic users.</p>
        </div>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Additional Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Medical Treatment</h4>
        <ul>
          <li><a href="https://www.spravato.com/">Spravato Treatment Centers</a> - FDA-approved esketamine</li>
          <li><a href="https://www.ketamineadvocacynetwork.org/">Ketamine Advocacy Network</a> - Treatment access</li>
          <li><a href="https://psychedelicmedicine.com/ketamine">Psychedelic Medicine</a> - Treatment info</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Research & Education</h4>
        <ul>
          <li><a href="https://maps.org/research/ketamine">MAPS Ketamine Research</a> - Scientific studies</li>
          <li><a href="https://psychonautwiki.org/wiki/Ketamine">PsychonautWiki</a> - Comprehensive information</li>
          <li><a href="https://www.erowid.org/chemicals/ketamine/">Erowid Ketamine Vault</a> - Experience reports</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Harm Reduction</h4>
        <ul>
          <li><a href="https://dancesafe.org/">DanceSafe</a> - Testing and safety info</li>
          <li><a href="https://www.reddit.com/r/ketamine/">/r/Ketamine</a> - Community discussion</li>
          <li><a href="https://bluelight.org/">Bluelight</a> - Harm reduction forum</li>
        </ul>
      </div>
    </div>
  </div>

</div>
    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/Dyo-s-Dubious-Domain/js/lunr.min.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/search.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/substance-integration.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/profile.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/friends.js"></script>
</body>
</html>